Print Page | Close Window

2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
04/03/17Verastem to Present at the 16th Annual Needham Healthcare Conference
BOSTON--(BUSINESS WIRE)--Apr. 3, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th at 3:00 p.m. ET at The Westin Grand Central in New York City. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived presentat... 
Printer Friendly Version
04/02/17Data on Verastem’s Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American Association for Cancer Research Annual Meeting
BOSTON--(BUSINESS WIRE)--Apr. 2, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of data for its lead focal adhesion kinase (FAK) inhibitor, defactinib, by the Company’s scientific collaborator David G. DeNardo, PhD, Assistant Professor of Medicine, Division of Oncology, Department of Immunology, Washington University School of Medicine in St. Louis, at the 2017 ... 
Printer Friendly Version
03/23/17Verastem Reports Year-End 2016 Financial Results
BOSTON--(BUSINESS WIRE)--Mar. 23, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the year ended December 31, 2016, and also provided an overview of certain corporate developments. “2016 was a year of significant achievement for Verastem with the in-licensing of duvelisib, a late-stage, clinical product candidate with broad potential across B-cell and T... 
Printer Friendly Version
03/16/17Verastem to Host Conference Call on March 23rd to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights
BOSTON--(BUSINESS WIRE)--Mar. 16, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will host a conference call and webcast on Thursday, March 23, 2017 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2016. The call can be accessed by dialing (877) 341-5660 (U.S. and Canada) or (315... 
Printer Friendly Version
03/15/17Verastem to Present at the Oppenheimer 27th Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Mar. 15, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21st at 2:10 p.m. ET at the Westin Grand Central in New York City. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived pre... 
Printer Friendly Version
03/07/17Verastem to Present at the 29th Annual ROTH Conference
BOSTON--(BUSINESS WIRE)--Mar. 7, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 29th Annual ROTH Conference on Monday, March 13th at 4:00 p.m. PT at the Ritz Carlton in Dana Point, CA. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived presentation will be available for 9... 
Printer Friendly Version
02/07/17Verastem to Present at 19th Annual BIO CEO & Investor Conference
BOSTON--(BUSINESS WIRE)--Feb. 7, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14th at 9:00 a.m. ET at the Waldorf Astoria Hotel in New York City. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived ... 
Printer Friendly Version
01/26/17Verastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer
Phase 1/2 Study Expected to Enroll Approximately 100 Patients at up to 15 sites in the U.S. BOSTON--(BUSINESS WIRE)--Jan. 26, 2017-- Verastem, Inc., (NASDAQ:VSTM) today announced dosing of the first patient in a new clinical trial evaluating avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s defactinib**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanc... 
Printer Friendly Version
01/19/17Verastem Announces Executive Leadership Appointments and Changes
Hagop Youssoufian, MSc, MD Named Head of Hematology and Oncology Development; Greg I. Berk, MD to Transition to Senior Advisor and Member of Clinical and Scientific Advisory Board Lori Kunkel, MD and Edmund J. Pezalla, MD, MPH Appointed to Clinical and Scientific Advisory Board Michael Ferraresso to Join the Company as Vice President, Commercial Operations BOSTON--(BUSINESS WIRE)--Jan. 19, 2017-- Verastem, Inc. (NASDAQ: ... 
Printer Friendly Version